Use of Conformationally Restricted Benzamidines as Arginine Surrogates in the Design of Platelet GPIIb-IIIa Receptor Antagonists
Daniel J. Sall(Eli Lilly (United States)), Joseph A. Jakubowski(Indiana Biosciences Research Institute), Robert M. Scarborough(Scripps Research Institute), Cathy S. Harms(Eli Lilly (United States)), James H. Wikel(Eli Lilly (United States)), Jack W. Rose(Eli Lilly (United States)), Robert T. Vasileff, Michael L. Denney(Eli Lilly (United States)), Jefferson R. McCowan(Eli Lilly (United States)), Jolie Bastian(Eli Lilly (United States)), Ann Arfsten(Scripps Research Institute), Suzane L. Um(Eli Lilly (United States)), Barbara G. Utterback(Eli Lilly (United States)), Virginia L. Wyss(Eli Lilly (United States)), Mark S. Smyth(Eli Lilly (United States)), J. M. JUN. MORIN
Cited by 22
Related Papers
Drotrecogin Alfa (Activated) for Adults with Severe Sepsis and a Low Risk of Death
|New England Journal of Medicine|2005|890
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
|New England Journal of Medicine|2013|651
A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents
|Journal of the American College of Cardiology|2012|617